Expression of phospho-p38MAPK in asthmatic rats with airway remodeling the effect on proliferation of mucous cells and the regulation of budesonide

Abstract

Abstract: AIM: To investigate the protein ex-pression of phospho-p38MAPK in asthmatic rats with airway remodeling and its effects on proliferation of mu-cous cells and the regulation role of budesonide. METHODS: Thirty male rats were randomly divided into control group (Group C, n =10) , airway remodeling group(Group A, n=10) and budesonide treated group (Group B, n =10) .The asthmatic rat model with airway remodeling was established. The lung tis-sue was observed by Hematoxylin and eosin staining, Masson' s Trichrome stain, Periodic Acide Schiff' and immunohistochemistry staining .RESULTS: Pathological changes of airway remodeling were found under light microscope and TEM .Compared with Group A, the pathologic change in group B was relieved. The results of image analysis: compared with Group A, the total bronchial wall area(Wat) and the smooth muscle area (Wam) and the percentage of mucous cells in rat air-way epithelium were significantly decreased in Group C and Group B, but the Wat and Wam in group B were higher than those in Group C. Compared with Group A, the contents of phospho-p38MAPK protein in group B and group C were decreased .There were significant positive correlation between the contents of phospho-p38MAPK and percentage of mucous cells(n =30, r = 0.813, P<0.01) .CONCLUSION: High expression of phospho-p38MAPK might precipitate the proliferation of mucous cells in asthmatic rats. Budesonide can inhibit the expression of phospho-p38MAPK protein in the airway epithelium of asthmatic rats with airway re-modeling, by which might inhibit proliferation of mucous cells.

Key words: asthma, rat, airway remodeling, mucous cell, budesonide

CLC Number:

R965.2

ZHENG Yang-ming, LI Chang-chong, Zhang Wei-xi, GUAN Xiao-jun. Expression of phospho-p38MAPK in asthmatic rats with airway remodeling the effect on proliferation of mucous cells and the regulation of budesonide[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(8): 866-871.

References

[1] Holgate ST, Davies DE, Puddicombe S, et al.Mecha-nisms of airway epithelial damage:epithelial-mesenchymal interactions in the pathogenesis of asthma[J] .Eur Respir J Suppl, 2003, 44:24-29.
[2] Newton R, Holden N, et al.Inhibitorsof p38mitogen-ac-tivated protein kinase:potential as anti -inflammatory agentsin asthma[J] ? Bio Drugs, 2003, 17(2):113-129.
[3] Palmans E, Kips JC, et al.Pauwels RA.Prolonged aller-gen exposure induces structural airway changes in sensi-tized rats[J] .Am J Respir Crit Care Med, 2000, 161(2): 627-635.
[4] Bai A, Eidelman DH, Hogg JC, et al.Proposed nomen-clature for quantifying subdivisions of the bronchial wall[J] .J Appl Physiol, 1994, 77(2):1011-1014.
[5] Fujisswa T, Ide K, Holtzman MJ, et al.Involvement of the p38MAPK pathway in IL-13-induced mucous cell metaplasia in mouse tracheal epithelial cells[J] .Respirol-ogy, 2008, 13(2):191-202.
[6] Wei Duan, Jasmine H.P.Chan, Kelly Mckay, et al. In-haled p38 Mitogen-activated Protein Kinase Antisense Oli-gonucleotide AttenuatesAsthma inMice[J] .Am J Respir Crit Care Med, 2005, 171:571-578.
[7] Pelaia G, Cuda G, Vatrella A, et al.Effectsof glucocor-ticoids on activation of c-JunN-terminal, extracellular sig-nal -regulated, and p38 MAP kinases in human pulmonary endothelialcells[J] .Biochem Pharmacol, 2001, 62(12): 1719-1724.
[8] Hashimoto S, GonY, Matsumoto K, et al. Inhalant corti-costeroids inhibit hyperosmolarity-induced, and cooling and rewarming-induced interleukin-8 and RANTES pro-duction by human bronchial epithelial cells[J] .Am J Re-spir Crit Care Med, 2000, 162(3):1075-1080.
[9] Chetta A, Zanini A, ForesiA, et al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone[J] .Am J Respir Crit Care Med, 2003, 167(5):751-757.
[10] Kawaguchi M, Kokubu F, Matsukura S, et al.Induction of C-X-C chemokines, growth-related oncogene alpha ex-pression, and epithelial cell-derived neutrophil -activating protein-78 by ML-1 (interleukin-17F) involves activation of Raf1-mitogen-activated protein kinase kinase-extracellu-lar signal-regulated kinase 1 2 pathway[J] .J Pharmacol Exp Ther, 2003, 307(3):1213-1220.
[11] 罗丽丹, 金小红, 董夏生, 等.生长相关癌基因α在大鼠哮喘中的表达意义及地塞米松对其的影响[J] .中国临床药理学和治疗学, 2008, 13(4):396-400.
[12] 管小俊, 张维溪, 李昌崇, 等.细胞外信号调节激酶和转化生长因子在哮喘气道重塑中的作用以及糖皮质激素的调控[J] .中华医学杂志, 2007, 87(25):1767-1772.

[1]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[2]	CHEN Qun, ZHU Heping, YUAN Xiaolong. Analysis of 197 cases of pentoxifylline injection and exploring supervision mode of rational drug use in hospitals [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 948-953.
[3]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[4]	XU Xiuhe, HE Xiaoli, ZHOU Jiashun, PAN Lizhu, ZHOU Zhuojun, LI Jiayue, WANG Caixia, YUAN Wei, ZHU Guiqi. Effects of scacia honey on serum uric acid level and renal injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 743-750.
[5]	WANG Lin, YU Jianguo, LI Xiao, LUAN Jiajie. Establish and implement a pre-prescription system for outpatient based on Six Sigma DMAIC model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 780-787.
[6]	WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong. Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
[7]	WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken . Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
[8]	LI Hongqin, CAO Limin, JIN Manyi, WANG Jianlong, CHAI Xiaoping, TIAN Miaomiao. Effects of different dosage forms of Qianzheng powder on facial nerve injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 617-623.
[9]	ZHANG Wei, LIU Lei, GUAN Shaoyang, SHENG Zhao, SUN Wenwen. Analysis of the diagnostic value of fine-needle aspiration cytology and BRAF and RAS gene mutation screening for thyroid cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 653-657.
[10]	WU Xiongzhi, WANG Xuan, XU Siqi, JU Xia, WANG Shengbin, CHEN Yongquan. A comparative investigation of the impact of oral midazolam solution and dexmedetomidine nasal spray on preoperative anxiety in pediatric patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 666-670.
[11]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[12]	CHEN Cheng, DENG Yu, GONG Youlan, ZHANG Zhenming, DUAN Wulei, QING Jun, ZHANG Bo. Research progress of the classical TCM formula Huaihua powder [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 697-704.
[13]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[14]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[15]	DANG Zilong, LIU Haiyang, ZHANG Yangfan, LIU Jinfeng, ZHANG Tianwei, LI Bin, GUO Hong, CHENG Wenyuan, XU Xiaohui, LI Yile, WEI Yuhui, WU Xin'an. Optimization strategy of antibiotic dosing regimen in intensive care unit patients with augmented renal clearance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 561-571.